| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St. Mary's Hospital, London, W2 1NY, UK; Medicinal Chemistry and Sterix Ltd, Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK
* To whom correspondence should be addressed. E-mail: m.reed{at}imperial.ac.uk.
Steroid sulfatase (STS) is responsible for the hydrolysis of aryl and alkyl steroid sulfates and therefore has a pivotal role in regulating the formation of biologically active steroids. The enzyme is widely distributed throughout the body and its action is implicated in physiological processes and pathological conditions. The crystal structure of the enzyme has been resolved but relatively little is known about what regulates its expression or activity. Research into the control and inhibition of this enzyme has been stimulated by its important role in supporting the growth of hormone-dependent tumors of the breast and prostate. STS is responsible for the hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate to estrone and dehydroepiandrosterone respectively, both of which can be converted to steroids with estrogenic properties (i.e. estradiol and androstenediol) that can stimulate tumor growth. STS expression is increased in breast tumors and has prognostic significance. The role of STS in supporting tumor growth prompted the development of potent STS inhibitors. Several steroidal and non-steroidal STS inhibitors are now available with the irreversible type of inhibitor having a phenol sulfamate ester as their active pharmacophore. One such inhibitor, 667 COUMATE, has now entered a Phase I trial in postmenopausal women with breast cancer. The skin is also an important site of STS activity and deficiency of this enzyme is associated with X-linked ichthyosis. STS may also be involved in regulating part of the immune response and some aspects of cognitive function. The development of potent STS inhibitors will allow the role that this enzyme has in physiological and pathological processes to be investigated.
This article has been cited by other articles:
 |
|
 |
|
  P. A. Foster, S. K. Chander, S. P. Newman, L.W. L. Woo, O. B. Sutcliffe, C. Bubert, D. Zhou, S. Chen, B. V.L. Potter, M. J. Reed, et al. A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor Clin. Cancer Res., October 15, 2008; 14(20): 6469 - 6477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Paitz and R. M. Bowden A proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects Integr. Comp. Biol., September 1, 2008; 48(3): 419 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. van der Deure, E. C. H. Friesema, F. J. de Jong, Y. B. de Rijke, F. H. de Jong, A. G. Uitterlinden, M. M. B. Breteler, R. P. Peeters, and T. J. Visser Organic Anion Transporter 1B1: An Important Factor in Hepatic Thyroid Hormone and Estrogen Transport and Metabolism Endocrinology, September 1, 2008; 149(9): 4695 - 4701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hoon Lee, H. Gong, S. Khadem, Y. Lu, X. Gao, S. Li, J. Zhang, and W. Xie Androgen Deprivation by Activating the Liver X Receptor Endocrinology, August 1, 2008; 149(8): 3778 - 3788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.W. L. Woo, D. S. Fischer, C. M. Sharland, M. Trusselle, P. A. Foster, S. K. Chander, A. Di Fiore, C. T. Supuran, G. De Simone, A. Purohit, et al. Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography Mol. Cancer Ther., August 1, 2008; 7(8): 2435 - 2444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Purohit, L. Fusi, J. Brosens, L.W.L. Woo, B.V.L. Potter, and M.J. Reed Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy Hum. Reprod., February 1, 2008; 23(2): 290 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sugawara, E. Nomura, and N. Hoshi Cholesterol sulphate affects production of steroid hormones by reducing steroidogenic acute regulatory protein level in adrenocortical cells J. Endocrinol., December 1, 2007; 195(3): 451 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Geyer, B. Doring, K. Meerkamp, B. Ugele, N. Bakhiya, C. F. Fernandes, J. R. Godoy, H. Glatt, and E. Petzinger Cloning and Functional Characterization of Human Sodium-dependent Organic Anion Transporter (SLC10A6) J. Biol. Chem., July 6, 2007; 282(27): 19728 - 19741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Goodarzi, H. J. Antoine, and R. Azziz Genes for Enzymes Regulating Dehydroepiandrosterone Sulfonation Are Associated with Levels of Dehydroepiandrosterone Sulfate in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2659 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rice and S. A Whitehead Phytoestrogens and breast cancer -promoters or protectors? Endocr. Relat. Cancer, December 1, 2006; 13(4): 995 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Foster, S. P. Newman, S. K. Chander, C. Stengel, R. Jhalli, L. L.W. Woo, B. V.L. Potter, M. J. Reed, and A. Purohit In vivo Efficacy of STX213, A Second-Generation Steroid Sulfatase Inhibitor, for Hormone-Dependent Breast Cancer Therapy. Clin. Cancer Res., September 15, 2006; 12(18): 5543 - 5549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L D. Valle, V Toffolo, A Nardi, C Fiore, P Bernante, R Di Liddo, P. Parnigotto, and L Colombo Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue. J. Endocrinol., July 1, 2006; 190(1): 129 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Teuscher, R. Noubade, K. Spach, B. McElvany, J. Y. Bunn, P. D. Fillmore, J. F. Zachary, and E. P. Blankenhorn Evidence that the Y chromosome influences autoimmune disease in male and female mice PNAS, May 23, 2006; 103(21): 8024 - 8029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mesia-Vela, R. I. Sanchez, K. R. Reuhl, A. H. Conney, and F. C. Kauffman Phenobarbital Treatment Inhibits the Formation of Estradiol-Dependent Mammary Tumors in the August-Copenhagen Irish Rat J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 590 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Stanway, A. Purohit, L.W. L. Woo, S. Sufi, D. Vigushin, R. Ward, R. H. Wilson, F. Z. Stanczyk, N. Dobbs, E. Kulinskaya, et al. Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor Clin. Cancer Res., March 1, 2006; 12(5): 1585 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Honma, K. Takubo, M. Sawabe, T. Arai, F. Akiyama, G. Sakamoto, T. Utsumi, N. Yoshimura, and N. Harada Estrogen-Metabolizing Enzymes in Breast Cancers from Women over the Age of 80 Years J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 607 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Suzuki, Y. Miki, Y. Nakamura, T. Moriya, K. Ito, N. Ohuchi, and H. Sasano Sex steroid-producing enzymes in human breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 701 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hammer, S. Subtil, P. Lux, C. Maser-Gluth, P. M. Stewart, B. Allolio, and W. Arlt No Evidence for Hepatic Conversion of Dehydroepiandrosterone (DHEA) Sulfate to DHEA: In Vivo and in Vitro Studies J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3600 - 3605. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
